Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

NCT02227550 is registered in ClinicalTrials.gov with Atrial Fibrillation Network as lead sponsor.

NCT NCT02227550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation
Lead sponsor
Atrial Fibrillation Network
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2014
Completion date
September 30, 2017
Enrollment
676 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation